Detalhe da pesquisa
1.
Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia.
Value Health
; 25(10): 1685-1695, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35537984
2.
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Br J Haematol
; 193(1): 15-25, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33216986
3.
Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017).
Ann Hematol
; 100(10): 2501-2512, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34279676
4.
Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience.
Support Care Cancer
; 29(8): 4867-4874, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33547525
5.
Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs.
Oncologist
; 24(11): e1236-e1250, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31346132
6.
Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.
Oncology
; 94(5): 274-280, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29471300
7.
A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.
Am J Hematol
; 93(4): 486-493, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29266344
8.
Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.
Blood
; 125(2): 236-41, 2015 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-25395425
9.
Extranodal presentation in limited-stage diffuse large Bcell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001.
Haematologica
; 107(11): 2732-2736, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35833300
10.
A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma.
Oncology
; 93(6): 401-405, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28869931
11.
Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI.
Mol Imaging
; 152016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27140422
12.
Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review.
Biol Blood Marrow Transplant
; 22(7): 1182-1196, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26899562
13.
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.
Blood
; 124(8): 1259-65, 2014 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25016003
14.
Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies.
Haematologica
; 106(7): 2022-2025, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33504141
15.
Limited Stage Aggressive Non-Hodgkin Lymphoma: What Is Optimal Therapy?
Curr Treat Options Oncol
; 17(9): 45, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27423794
16.
Limited-stage DLBCL: it's patient selection.
Blood
; 131(2): 155-156, 2018 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29326347
17.
Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma.
Am J Hematol
; 89(6): 639-45, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24633940
18.
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.
Cancer
; 119(2): 371-9, 2013 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22833464
19.
Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort.
Haematologica
; 103(4): e151-e153, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29472351
20.
AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Int J Cancer
; 130(12): 2997-3005, 2012 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21796626